US2006166930A1PendingUtilityA1
Medicinal composition for ophthal use containing acetylated hyaluronic acid
Est. expiryFeb 27, 2023(expired)· nominal 20-yr term from priority
A61K 31/728A61P 27/04A61P 27/02C08B 37/0072C08B 37/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides an ophthalmic pharmaceutical composition containing acetylated hyaluronic acid and a pharmacologically acceptable carrier. Preferably, the average molecular weight of the acetylated hyaluronic acid is 10,000 to 1,000,000, and the acetyl group substitution number is from 2.0 to 4.0. In a preferred embodiment, this ophthalmic pharmaceutical composition is used in the treatment or prevention of dry eye, and in an even more preferred embodiment it is a dry-eye instillation.
Claims
exact text as granted — not AI-modified1 . An ophthalmic pharmaceutical composition comprising acetylated hyaluronic acid and a pharmacologically acceptable carrier.
2 . The ophthalmic pharmaceutical composition according to claim 1 , wherein the average molecular weight of the acetylated hyaluronic acid is from 10,000 to 1,000,000, and the acetyl group substitution number is 2.0 to 4.0
3 . The ophthalmic pharmaceutical composition according to claim 1 , which is used for the treatment of dry eye.
4 . The ophthalmic pharmaceutical composition according to claim 3 , which is a dry-eye instillation.
5 . The ophthalmic pharmaceutical composition according to claim 2 , which is used for the treatment of dry eye.Join the waitlist — get patent alerts
Track US2006166930A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.